GYRE
Price
$7.22
Change
-$0.07 (-0.96%)
Updated
Sep 26, 12:25 PM (EDT)
Capitalization
662.13M
47 days until earnings call
SPRC
Price
$4.51
Change
-$1.58 (-25.94%)
Updated
Sep 26, 01:29 PM (EDT)
Capitalization
9.88M
Interact to see
Advertisement

GYRE vs SPRC

Header iconGYRE vs SPRC Comparison
Open Charts GYRE vs SPRCBanner chart's image
Gyre Therapeutics
Price$7.22
Change-$0.07 (-0.96%)
Volume$700
Capitalization662.13M
SciSparc
Price$4.51
Change-$1.58 (-25.94%)
Volume$262
Capitalization9.88M
GYRE vs SPRC Comparison Chart in %
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. SPRC commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Buy and SPRC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (GYRE: $7.29 vs. SPRC: $6.09)
Brand notoriety: GYRE and SPRC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 48% vs. SPRC: 1670%
Market capitalization -- GYRE: $662.13M vs. SPRC: $9.88M
GYRE [@Biotechnology] is valued at $662.13M. SPRC’s [@Biotechnology] market capitalization is $9.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green whileSPRC’s FA Score has 1 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • SPRC’s FA Score: 1 green, 4 red.
According to our system of comparison, both GYRE and SPRC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 4 TA indicator(s) are bullish while SPRC’s TA Score has 5 bullish TA indicator(s).

  • GYRE’s TA Score: 4 bullish, 5 bearish.
  • SPRC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SPRC is a better buy in the short-term than GYRE.

Price Growth

GYRE (@Biotechnology) experienced а -5.20% price change this week, while SPRC (@Biotechnology) price change was +30.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.01%. For the same industry, the average monthly price growth was +9.06%, and the average quarterly price growth was +48.80%.

Reported Earning Dates

GYRE is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($662M) has a higher market cap than SPRC($9.88M). GYRE has higher P/E ratio than SPRC: GYRE (364.50) vs SPRC (0.00). SPRC YTD gains are higher at: -19.444 vs. GYRE (-39.752). GYRE has higher annual earnings (EBITDA): 11.5M vs. SPRC (-6.97M). GYRE has more cash in the bank: 54.4M vs. SPRC (1.54M). SPRC has less debt than GYRE: SPRC (46K) vs GYRE (1.39M). GYRE has higher revenues than SPRC: GYRE (102M) vs SPRC (1.31M).
GYRESPRCGYRE / SPRC
Capitalization662M9.88M6,700%
EBITDA11.5M-6.97M-165%
Gain YTD-39.752-19.444204%
P/E Ratio364.500.0018,325,792%
Revenue102M1.31M7,810%
Total Cash54.4M1.54M3,532%
Total Debt1.39M46K3,028%
FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
57
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
PROFIT vs RISK RATING
1..100
90
SMR RATING
1..100
84
PRICE GROWTH RATING
1..100
85
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GYRESPRC
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 19 days ago
81%
Bullish Trend 8 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ACNT12.680.11
+0.88%
Ascent Industries Co
OSPN15.99-0.13
-0.81%
OneSpan
PKG213.14-2.18
-1.01%
Packaging Corp
IOTR0.37N/A
-1.25%
iOThree Ltd
APLS22.22-0.54
-2.37%
Apellis Pharmaceuticals

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-1.09%
SPRC - GYRE
38%
Loosely correlated
+59.01%
RCKT - GYRE
36%
Loosely correlated
-3.92%
BEAM - GYRE
35%
Loosely correlated
-2.12%
IMVT - GYRE
34%
Loosely correlated
+1.36%
AURA - GYRE
34%
Loosely correlated
-4.70%
More

SPRC and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRC has been loosely correlated with ASMB. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRC jumps, then ASMB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRC
1D Price
Change %
SPRC100%
+59.01%
ASMB - SPRC
45%
Loosely correlated
-0.51%
GYRE - SPRC
38%
Loosely correlated
-1.09%
MTNB - SPRC
36%
Loosely correlated
-2.08%
ALZN - SPRC
31%
Poorly correlated
-0.84%
NKTX - SPRC
30%
Poorly correlated
-2.91%
More